12 Health Care Stocks Moving In Monday's After-Market Session
Portfolio Pulse from Benzinga Insights
In Monday's after-market session, several healthcare stocks showed significant movement. CareMax, Burning Rock Biotech, LifeMD, SCWorx, Innate Pharma, and Clearside Biomedical were among the gainers, with notable increases in their stock prices. On the other hand, CytomX Therapeutics, ACADIA Pharmaceuticals, PaxMedica, Cognition Therapeutics, Ocular Therapeutix, and Atreca experienced declines. LifeMD's Q4 earnings were released, contributing to its stock price increase, while CytomX Therapeutics and Ocular Therapeutix also released their Q4 earnings, which may have influenced their stock price drops.
March 11, 2024 | 9:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Burning Rock Biotech's stock rose by 12.34% to $0.91, with a market value of $93.4 million.
The upward movement in Burning Rock Biotech's stock suggests a positive outlook, potentially leading to further gains.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 90
POSITIVE IMPACT
CareMax's stock increased by 16.9% to $8.0, with a market value of $29.9 million.
The significant increase in CareMax's stock price indicates positive market sentiment, likely to continue in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
LifeMD's shares increased by 11.19% to $8.84, with a market value of $346.5 million, following the release of Q4 earnings.
The release of Q4 earnings positively impacted LifeMD's stock, indicating strong performance and potential for continued growth.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 95
NEGATIVE IMPACT
CytomX Therapeutics' stock declined by 22.3% to $1.95, with a market value of $130.6 million, after the Q4 earnings report.
The decline in CytomX Therapeutics' stock post-Q4 earnings suggests the results may have not met market expectations, likely impacting short-term performance.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 95
NEGATIVE IMPACT
Ocular Therapeutix's stock decreased by 9.05% to $8.85, with a market cap of $1.0 billion, following the Q4 earnings release.
The drop in Ocular Therapeutix's stock post-Q4 earnings indicates the market's reaction to the earnings report, suggesting a negative short-term impact.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 95